Records of data processing activity for study of the “Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV- during the Omicron period”

Records of data processing activity for study of the “Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV- during the Omicron period”

European Medicines Agency's data protection notice on the study of the “Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV- during the Omicron period”

European Medicines Agency's data protection notice on the study of the “Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV- during the Omicron period”

Human medicines European public assessment report (EPAR): Pregabalin Mylan, pregabalin, Date of authorisation: 24/06/2015, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Pregabalin Mylan, pregabalin, Date of authorisation: 24/06/2015, Revision: 17, Status: Authorised

Pharmacovigilance Risk Assessment Committee (PRAC): 13-16 May 2024, European Medicines Agency, Amsterdam, the Netherlands, from 13 May 2024 to 16 May 2024

Pharmacovigilance Risk Assessment Committee (PRAC): 13-16 May 2024, European Medicines Agency, Amsterdam, the Netherlands, from 13 May 2024 to 16 May 2024

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness